Investment Research Overview
GlassesOff, Inc. (OTC: GLSO) represents a unique chapter in the digital health sector. Unlike many micro-cap biotechnology companies pursuing pharmaceutical treatments, GlassesOff focused on software-based vision improvement through neuroscience. Its flagship product, the GlassesOff mobile application, was designed to improve near vision by training the brain’s visual processing system rather than altering the physical characteristics of the eye.
While the company attracted significant attention during the early wave of digital therapeutics, investors should recognize that GlassesOff today differs substantially from the growth story originally presented to public markets. Much of the company’s technology remains scientifically interesting, but its commercial activity appears to have slowed dramatically over recent years.
Company Background
GlassesOff traces its origins to Israel, where researchers developed a software platform based on decades of neuroscience research into visual perception and neuroplasticity.Unlike conventional vision correction products, the company attempted to address one specific condition:
Age-related presbyopia—the gradual loss of the eye’s ability to focus on nearby objects, affecting nearly everyone after age forty.
Instead of correcting the eye itself, GlassesOff attempted to improve how the brain interprets visual information.
The company ultimately became publicly traded in the United States under the OTC ticker GLSO, positioning itself within the rapidly emerging digital healthcare and mobile medical application market. During its early public years, the company achieved a market capitalization exceeding $100 million despite generating relatively modest revenues, reflecting investor enthusiasm for digital therapeutics.
The Technology
The central concept behind GlassesOff is surprisingly different from traditional eye-care solutions.
Human vision depends upon two systems:
- the eye capturing an image
- the brain interpreting that image
As people age, presbyopia reduces image quality because the eye’s lens gradually loses flexibility. GlassesOff argued that although the eye cannot easily be restored, the brain’s visual cortex can become more efficient at processing degraded visual signals.
The application therefore uses repeated visual exercises based on Gabor patches—simple striped visual patterns widely used in neuroscience—to strengthen contrast sensitivity, processing speed, and visual discrimination.
Rather than exercising the eye muscles, users train the brain itself.
The typical program involved:
- approximately 12-minute sessions
- three sessions per week
- training lasting roughly two to three months
Algorithms continually adjusted exercise difficulty according to user performance, creating personalized training plans.
Scientific Foundation
One of GlassesOff’s strongest differentiators was that it was not built solely on marketing claims.
Its technology originated from research led by neuroscientist Professor Uri Polat, whose work focused on visual neuroplasticity.
Clinical studies suggested improvements in:
- reading speed
- contrast sensitivity
- visual processing
- small-font recognition
Importantly, the company never claimed to cure presbyopia.
Instead, the objective was improving functional reading ability by allowing the brain to extract more useful information from blurred retinal images.
This distinction made GlassesOff one of the earliest commercial examples of what is now commonly referred to as digital therapeutics.
Business Model
GlassesOff adopted a software-as-a-service subscription model long before subscription healthcare apps became common.
Revenue sources included:
- monthly subscriptions
- quarterly subscriptions
- mobile app purchases
- personalized vision training programs
The company avoided manufacturing costs associated with medical devices, allowing gross margins to remain attractive if customer acquisition costs could be controlled.
Because the application required no specialized hardware, scalability depended almost entirely on user adoption.
Market Opportunity
The potential addressable market appeared enormous.
Worldwide:
- more than one billion people eventually develop presbyopia
- aging populations continue expanding
- smartphone adoption became nearly universal
Unlike LASIK surgery or prescription reading glasses, software-based vision improvement offered:
- low distribution costs
- recurring revenue
- direct consumer marketing
- global availability
These characteristics initially attracted considerable investor interest.
Competitive Landscape
GlassesOff competed across several different healthcare segments rather than against a single category.
Traditional Vision Correction
- Reading glasses
- Progressive lenses
- Contact lenses
- LASIK surgery
These solutions physically compensate for deteriorating eyesight rather than attempting neurological improvement.
Digital Vision Training
Several companies later entered cognitive vision training markets, including applications emphasizing:
- eye exercises
- reaction speed
- visual acuity
- sports vision enhancement
However, relatively few possessed published neuroscience research comparable to GlassesOff’s early academic foundation.
Digital Therapeutics
Perhaps the most relevant comparison today is the broader digital therapeutics industry.
Companies increasingly develop software intended to improve chronic medical conditions through behavioral, neurological, or cognitive interventions instead of pharmaceuticals.
This sector has expanded substantially since GlassesOff launched, suggesting that its original concept was ahead of its time.
Competitive Advantages
Historically, GlassesOff possessed several meaningful strengths.
Scientific credibility: Unlike many wellness applications, its methods originated from peer-reviewed neuroscience research.
Personalization: Training automatically adapted to individual performance.
Pure software economics: No inventory, manufacturing, or distribution infrastructure was required.
Large addressable market: Presbyopia affects virtually every aging adult.
Challenges
Despite its promising concept, GlassesOff faced significant obstacles.
Consumer skepticism
Many consumers found it difficult to believe that a smartphone application could improve vision.
Healthcare software often requires greater educational marketing than conventional consumer applications.
Clinical validation
Although published studies supported aspects of the technology, widespread physician adoption requires extensive long-term evidence.
Medical professionals generally remain cautious before recommending software-based treatments.
User retention
The application required repeated training sessions over several months.
Like many wellness applications, long-term engagement likely represented a major commercial challenge.
Commercial execution
Despite early publicity, GlassesOff appears to have experienced declining commercial momentum over time. Public information suggests that the original business substantially slowed, and the company no longer appears to maintain the level of visibility it once had.
Potential Investment Catalysts
Although GlassesOff appears largely inactive today, investors researching OTC companies would likely monitor several possible catalysts:
- licensing of proprietary neuroscience technology
- acquisition by a digital health company
- intellectual property monetization
- renewed commercialization of the platform
- strategic partnerships within telemedicine or digital therapeutics
At present, however, there is little publicly available evidence that such initiatives are actively underway. Investors should verify any future corporate announcements through current OTC disclosures before drawing conclusions.
Investment Risks
As with many dormant or thinly traded OTC securities, GlassesOff presents substantial risks.
These include:
- limited liquidity
- uncertain operating status
- sparse public reporting
- limited revenue visibility
- execution risk
- competitive digital health landscape
- regulatory uncertainty surrounding digital therapeutics
Because publicly available information has become increasingly limited, fundamental analysis is considerably more difficult than for actively reporting companies.
Conclusion
GlassesOff was an innovative pioneer that attempted to merge neuroscience, mobile computing, and healthcare long before digital therapeutics became a mainstream investment theme. Its software-based approach to treating presbyopia through neuroplasticity distinguished it from conventional vision correction products and attracted considerable attention during the early 2010s.
From a technology perspective, the company demonstrated how software could potentially address medical conditions without drugs or surgery. Commercially, however, GlassesOff appears to have struggled to sustain the momentum necessary to build a lasting digital health franchise. Public information suggests that operations and investor communications have become extremely limited in recent years.
For micro-cap investors, GLSO should be viewed primarily as a legacy digital health company rather than an actively growing operating business. Future investment value would likely depend less on renewed consumer adoption and more on any reactivation of corporate operations, monetization of intellectual property, strategic partnerships, or acquisition interest. Until evidence of such developments emerges, the stock remains highly speculative and should be approached with appropriate caution.
The affiliate may also receive restricted shares in the company in the future.
This compensation may affect the objectivity of our profile of the company.
You should do your own homework and consult an investment professional before making any investment decisions.
Read our full disclaimer here.
References
- MDDONLINE GlassesOff App Claims Vision Help
- Soft112 GlassesOff.2.1.8